Jun. 22 at 11:05 AM
$ABBV $APGE
AbbVie to acquire Apogee Therapeutics for
$135.11 per share in cash, or
$10.9B
AbbVie (ABBV) and Apogee Therapeutics (APGE) announced they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis and asthma. The acquisition complements AbbVie's existing immunology portfolio and accelerates AbbVie's clinical presence in the respiratory space. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for
$135.11 per share in cash.
The transaction values Apogee at a total equity value of approximately
$10.9B. The boards of directors of both companies have unanimously approved the transaction. This transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals. The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Apogee shareholders. Fairmount Funds Management LLC and Venrock Associates have entered into voting agreements in support of the transaction. The proposed transaction is expected to be accretive to AbbVie's adjusted diluted earnings per share beginning in 2032.
